ArticleGlobal cardiology science & practice2025
Heart failure with preserved ejection fraction: the impact of right heart failure on risk mortality in hospitalized COVID-19 patients: Cohort study.
Article in Global cardiology science & practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHeart failure is a clinical syndrome characterized by signs and symptoms of structural and/or functional alterations accompanied by impaired expulsion of blood or ventricular filling. COVID-19 contributes to circulatory failure and frequently induces or facilitates pulmonary artery thrombosis. HF can be a risk factor as well as a complication of COVID-19.
aimsThe purpose of this study was to evaluate the association between HFpEF isolate and RHF + HFpEF on mortality according to sex in hospitalized patients caused by COVID-19.
methodsA prospective cohort study was performed on hospitalized COVID-19 patients from February 2021 to October 2022. Patients ≥18 years with COVID-19 and an echocardiogram during their hospitalization were included. We excluded patients with HIV, shock, and with missing data.
resultsA total of 105 patients were included in this study. The median age was 64 years (50-76), 32% (
conclusionHeart failure is an important condition associated with poor prognosis irrespective of the cause of hospitalization. COVID-19 causes damage to the heart and is associated with "RHF and HFpEF". Furthermore, there were found an increased incidence of "RHF and HFpEF" in women.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.